KIZ

Across TCGA pan-cancer cohorts, KIZ Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated KIZ data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher KIZ Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KIZ expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, SCLC, and UCEC are the cancer types where KIZ Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	II,III,IV	0.142	0.782	<.001	33	view →
SCLC	OS	Median	III,IV	0.082	0.639	<.001	12	view →
UCEC	DFS	Median	All	0.959	0.611	.014	6	view →
COAD	OS	Median	II,III,IV	0.185	0.785	.023	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

KIZ–LIHC (OS)

Open the LIHC breakdown →